立即開始
warrenhochfeld

KERX bull run ahead of Auryxia label extension

看多
warrenhochfeld  
NASDAQ:KERX   None
Trend Analysis Beyond Technical Analysis KERX
2
0
trendanalysis beyondta kerx
Label Expansion Opportunity: seeking approval of Auryxia for the treatment of patients with iron deficiency anemia and non-dialysis dependent chronic kidney disease
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。